MENS:NASDAQJyong Biotech Ltd. Analysis
Data as of 2026-04-17 - not real-time
Latest Price
Risk Level: High
Executive Summary
Jyong Biotech Ltd. (MENS) trades at $2.59, just above its calculated support of $1.66 and well below its 52‑week high of $67. The stock sits slightly above its 20‑day SMA ($2.29) and 50‑day SMA ($2.14), indicating modest short‑term strength, while the 200‑day SMA remains far higher, underscoring a long‑term downtrend. Technicals are neutral with an RSI of 55 and a bullish MACD histogram, but volatility is extreme at ~98% and beta exceeds 2.5, pointing to amplified price swings. Fundamentally, the company reports zero revenue, negative EBITDA of $‑1.8M, a negative book value per share (‑$0.313) and a PB ratio of ‑8.27, while cash ($17M) is insufficient to cover debt ($35M). Recent news highlights completion of a global Phase III trial for its plant‑derived drug MCS‑2 and an Innovation Gold Award, suggesting potential upside if regulatory approval materializes.
Market Outlook
Short Term
< 1 yearKey Factors
- technical indicators are neutral with modest bullish bias
- price is near support but volatility is extreme
- liquidity is decreasing
Medium Term
1–3 yearsKey Factors
- absence of revenue and negative cash flow
- high beta and volatility amplify downside risk
- significant debt relative to cash
Long Term
> 3 yearsKey Factors
- potential regulatory approval of MCS‑2 after Phase III success
- unique plant‑derived therapeutic platform
- large market opportunity in BPH/LUTS and oncology
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.